<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04801563</url>
  </required_header>
  <id_info>
    <org_study_id>03/19</org_study_id>
    <nct_id>NCT04801563</nct_id>
  </id_info>
  <brief_title>Allogeneic HSCT in MDS Patients Based on Risk According to R-IPSS</brief_title>
  <official_title>Allogeneic Transplantation in Patients With Myelodysplastic Syndrome Based on Risk According to Revised-International Prognostic Scoring System (R-IPSS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Of Perugia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Of Perugia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An &quot;intention-to-treat&quot; study to evaluate the impact of allogeneic HSCT with Total Marrow and&#xD;
      Lymphoid irradiation (TMLI), followed by Treg/Tcon adoptive immunotherapy, on overall&#xD;
      survival in patients affected by Myelodysplastic Syndrome (MDS), according to IPSS-R.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MDS patients with Intermediate, High, or Very-High R-IPSS risk will be enrolled. Allogeneic&#xD;
      stem cell transplantation with regulatory and conventional T cell adoptive immunotherapy will&#xD;
      be proposed to eligible High and Very-High risk MDS patients. Intermediate risk MDS patients&#xD;
      will be assessed for risk modification every six months and moved to transplant in case of&#xD;
      increased risk. Intermediate risk MDS patients will be also evaluated for the presence of&#xD;
      molecular alterations (TP53, ASXL1, RUNX1). Overall survival of the entire cohort will be&#xD;
      assessed as primary endpoint. Incidence of Treatment Related Mortality, acute Graft versus&#xD;
      Host Disease, chronic Graft versus Host Disease, Relapse will be also assessed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 20, 2019</start_date>
  <completion_date type="Anticipated">September 19, 2025</completion_date>
  <primary_completion_date type="Anticipated">September 19, 2025</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
    <time_frame>4 years</time_frame>
    <description>We will evaluate overall survival in patients with intermediate/High/very-High risk MDS</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>MDS and Allogeneic Stem Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>SINGLE ARM</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>MDS and AlloHSCT</intervention_name>
    <description>Allogeneic stem cell transplantation, based on TMLI and followed by infusion of donor regulatory T cells and conventional T cells and purified donor CD34+ hematopoietic stem cells</description>
    <arm_group_label>SINGLE ARM</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients affected by Myelodysplastic Syndrome with IPSS-R INT, HIGH or VERY HIGH;&#xD;
&#xD;
          -  Age &lt;71 years;&#xD;
&#xD;
          -  Signature of the informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients affected by Myelodysplastic Syndrome with IPSS-R VERY LOW or LOW;&#xD;
&#xD;
          -  Patients affected by Myelodysplastic Syndrome/Myeloproliferative Neoplasm;&#xD;
&#xD;
          -  Age &gt;70 years;&#xD;
&#xD;
          -  No signature of the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Velardi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Of Perugia</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Antonio Pierini, MD</last_name>
    <phone>+390755784147</phone>
    <email>antonio.pierini@unipg.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Mara Merluzzi, MBiotech</last_name>
    <phone>+393482200239</phone>
    <email>maramerluzzi@libero.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University of Perugia</name>
      <address>
        <city>Perugia</city>
        <state>PG</state>
        <zip>06132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pierini, MD</last_name>
      <phone>+390755784147</phone>
      <email>antonio.pierini@unipg.it</email>
    </contact>
    <contact_backup>
      <last_name>MERLUZZI MARA</last_name>
      <phone>+393482200239</phone>
      <email>maramerluzzi@libero.it</email>
    </contact_backup>
    <investigator>
      <last_name>Cristina Mecucci, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Cynthia Aristei, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Antonio Pierini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Alessandra Carotti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Roberta La Starza, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Loredana Ruggeri, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Adelmo Terenzi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Chiara Camerini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Martina Quintini, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Simonetta Saldi, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Samanta Bonato, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Mario Griselli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <results_reference>
    <citation>Di Ianni M, Falzetti F, Carotti A, Terenzi A, Castellino F, Bonifacio E, Del Papa B, Zei T, Ostini RI, Cecchini D, Aloisi T, Perruccio K, Ruggeri L, Balucani C, Pierini A, Sportoletti P, Aristei C, Falini B, Reisner Y, Velardi A, Aversa F, Martelli MF. Tregs prevent GVHD and promote immune reconstitution in HLA-haploidentical transplantation. Blood. 2011 Apr 7;117(14):3921-8. doi: 10.1182/blood-2010-10-311894. Epub 2011 Feb 3.</citation>
    <PMID>21292771</PMID>
  </results_reference>
  <results_reference>
    <citation>Martelli MF, Di Ianni M, Ruggeri L, Falzetti F, Carotti A, Terenzi A, Pierini A, Massei MS, Amico L, Urbani E, Del Papa B, Zei T, Iacucci Ostini R, Cecchini D, Tognellini R, Reisner Y, Aversa F, Falini B, Velardi A. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014 Jul 24;124(4):638-44. doi: 10.1182/blood-2014-03-564401. Epub 2014 Jun 12.</citation>
    <PMID>24923299</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>February 28, 2021</study_first_submitted>
  <study_first_submitted_qc>March 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">March 17, 2021</study_first_posted>
  <last_update_submitted>March 11, 2021</last_update_submitted>
  <last_update_submitted_qc>March 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Of Perugia</investigator_affiliation>
    <investigator_full_name>Andrea Velardi</investigator_full_name>
    <investigator_title>FULL PROFESSOR</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

